CTX110
Live / Registered — Registered (as of 14 Jun 2022)
What this means for you
Registered since 14 Jun 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88296694
- Registration number
- 6760727
- Mark type
- Stylized text
- Filed
- 11 Feb 2019
- Published for opposition
- 17 Sept 2019
- Registered
- 14 Jun 2022
- Attorney of record
- Tiffany D. Gehrke
Goods and services
- Class 005 — Pharmaceuticals: Cells for medical or clinical use; pharmaceutical and biopharmaceutical agents for the treatment of cancer; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of cancer
- Class 042 — Scientific and technological services: Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders; gene editing, namely, pharmaceutical research and development
Owner
- CRISPR Therapeutics AG, ZUG V8, CH
- CRISPR Therapeutics AG, ZUG V8, CH
- CRISPR Therapeutics AG, Basel, CH
Prosecution history
- 14 Jun 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 Jun 2022 — REGISTERED-PRINCIPAL REGISTER
- 10 May 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 09 May 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 27 Jan 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 12 Jan 2022 — USE AMENDMENT FILED
- 27 Jan 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 12 Jan 2022 — TEAS STATEMENT OF USE RECEIVED
- 16 Nov 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Nov 2021 — SOU EXTENSION 4 GRANTED
- 12 Nov 2021 — SOU EXTENSION 4 FILED
- 12 Nov 2021 — SOU TEAS EXTENSION RECEIVED
- 16 Apr 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Apr 2021 — SOU EXTENSION 3 GRANTED
- 14 Apr 2021 — SOU EXTENSION 3 FILED